¼¼°èÀÇ °ÇÁ¶ Ç÷¹Ý äÃë Ä«µå ½ÃÀå
Dried Blood Spot Collection Cards
»óǰÄÚµå : 1774781
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 381 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,239,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,719,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°è °ÇÁ¶ Ç÷¹Ý äÃë Ä«µå ½ÃÀåÀº 2030³â±îÁö 4¾ï 6,810¸¸ ´Þ·¯¿¡ À̸¦ Àü¸Á

2024³â¿¡ 3¾ï 8,760¸¸ ´Þ·¯·Î ÃßÁ¤µÇ´Â °ÇÁ¶ Ç÷¹Ý äÃë Ä«µå ¼¼°è ½ÃÀåÀº 2024-2030³â°£ CAGR 3.2%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 4¾ï 6,810¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. º» º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ Whatman 903 Card´Â CAGR 4.3%¸¦ ³ªÅ¸³»°í, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 1¾ï 9,710¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. Ahlstrom 226 Card ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£Áß CAGR 2.2%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 1¾ï 560¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 6.2%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ °ÇÁ¶ Ç÷¹Ý äÃë Ä«µå ½ÃÀåÀº 2024³â¿¡ 1¾ï 560¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦´ë±¹ÀÎ Áß±¹Àº ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGR 6.2%·Î ¼ºÀåÀ» Áö¼ÓÇÏ¿©, 2030³â¿¡´Â ¿¹Ãø ½ÃÀå ±Ô¸ð 9,350¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±âŸ ÁÖ¸ñÇØ¾ß ÇÒ Áö¿ªº° ½ÃÀåÀ¸·Î¼­´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£Áß CAGRÀº °¢°¢ 1.2%¿Í 2.5%¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 1.8%·Î ¼ºÀåÇÒ Àü¸ÁÀÔ´Ï´Ù.

¼¼°èÀÇ °ÇÁ¶ Ç÷¹Ý äÃë Ä«µå ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

¿ø°Ý Áø´Ü°ú ºÐ»êÇü °Ë»ç¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼­ °ÇÁ¶ Ç÷¾× ¹ÝÁ¡ äÃë Ä«µå°¡ ÁÖ¸ñ¹Þ°Ô µÉ±î?

¼¼°è ÀÇ·á ½Ã½ºÅÛÀÌ ºÐ»êÇü Áø´Ü ¹× ¿ø°Ý ȯÀÚ ¸ð´ÏÅ͸µ¿¡ ÃÊÁ¡À» ¸ÂÃß°í ÀÖ´Â °¡¿îµ¥, DBS(Dry Blood Spot) äÃë Ä«µå´Â Àúħ½ÀÀûÀÌ°í ºñ¿ë È¿À²ÀûÀ̸ç È޴뼺ÀÌ ³ôÀº ¹ÙÀÌ¿À »ùÇøµ ¹æ¹ýÀ¸·Î Å« ÁÖ¸ñÀ» ¹Þ°í ÀÖ½À´Ï´Ù. DBS Ä«µåÀÇ À¯¿ë¼ºÀº ±âÁ¸ÀÇ Ã¤Ç÷ ÀÎÇÁ¶ó°¡ ºÎÁ·Çϰųª ÄݵåüÀÎ ¹°·ù°¡ ½ÇÇà ºÒ°¡´ÉÇÑ ÀÚ¿øÀÌ Á¦ÇÑµÈ È¯°æ¿¡¼­ ƯÈ÷ µÎµå·¯Áý´Ï´Ù. ƯÈ÷ µÎµå·¯Áý´Ï´Ù. DBS Ä«µå´Â °¨¿° °Ë»ç(HIV, °£¿° µî)ºÎÅÍ ½Å»ý¾Æ °ËÁø, ´ë»ç ÀÌ»ó °¨Áö, ¾àµ¿Çп¡ À̸£±â±îÁö, DBS Ä«µå´Â Á¢±Ù¼ºÀÌ ¶Ù¾î³ª°í È®Àå °¡´ÉÇÑ Áø´Ü¿¡ ÇʼöÀûÀÎ µµ±¸°¡ µÇ°í ÀÖÀ¸¸ç, Äڷγª19 ÆÒµ¥¹ÍÀº ¿ø°Ý °Ë»ç µµ±¸¿¡ ´ëÇÑ ¼ö¿ä¸¦ ´õ¿í °¡¼ÓÈ­ÇÏ¿© °¡Á¤¿ë °Ë»ç ŰƮ ¹× °øÁߺ¸°Ç °¨½Ã ÀÌ´Ï¼ÅÆ¼ºê DBS Ä«µå´Â ¿ìÆí Áø´Ü°ú Ä£¹Ðµµ°¡ ³ô°í, ³ÃÀå º¸°ü ¾øÀ̵µ »ùÇÃÀ» Àå±â°£ º¸°üÇÒ ¼ö ÀÖ¾î ¹ÙÀÌ¿À¹ðÅ© ¹× Á¾´Ü ¿¬±¸¿¡ ƯÈ÷ À¯¿ëÇÕ´Ï´Ù. °³ÀÎ ¸ÂÃãÇü ÀÇ·á¿Í ¿ªÇÐ ¸ð´ÏÅ͸µÀÌ È®»êµÊ¿¡ µû¶ó DBS äÃë Ä«µå´Â ÃÖ¼ÒÇÑÀÇ ÀÎÇÁ¶ó·Î ´ë±Ô¸ð °Ë»ç¸¦ °¡´ÉÇÏ°Ô ÇÏ´Â È¿À²ÀûÀ̰í ȯÀÚ Ä£È­ÀûÀÎ ¹æ¹ýÀÓÀÌ ÀÔÁõµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¼ö¿äÀÇ ÁøÈ­¿¡ µû¶ó DBS äÃë Ä«µå´Â Áß¾ÓÁýÁßÇü ½ÇÇè½Ç °Ë»ç¿¡¼­ ȯÀÚ Áß½ÉÀÇ ºÐ»êÇü ÇコÄÉ¾î ¸ðµ¨·Î ÀüȯÇÏ´Â µ¥ ÀÖ¾î ÇÙ½É ±â¼ú·Î ÀÚ¸®¸Å±èÇϰí ÀÖ½À´Ï´Ù.

DBS äÃë Ä«µåÀÇ Á¤È®µµ¿Í ÀÀ¿ëÀº ±â¼ú °³¼±À» ÅëÇØ ¾î¶»°Ô Çâ»óµÇ°í Àִ°¡?

½Ã·á äÃë Àç·á, ºÐ¼® °¨µµ ¹× ½ÇÇè½Ç ó¸®ÀÇ Çõ½ÅÀº °Ç½Ä Ç÷¾× ¹ÝÁ¡ äÃë Ä«µå¸¦ ´Ü¼øÇÑ ÇöÀå µµ±¸¿¡¼­ Á¤¹Ð Áø´Ü Ç÷§ÆûÀ¸·Î ¹ßÀü½Ã۰í ÀÖ½À´Ï´Ù. ÃֽŠDBS Ä«µå´Â ±ÕÀÏÇÑ Èí¼ö, ¸íÈ®ÇÑ ½ºÆÌ °æ°è, È­ÇÐÀû ¾ÈÁ¤¼ºÀ» °®Ãá °í±Þ ÇÊÅÍ ¿ëÁö¸¦ »ç¿ëÇÏ¿© Á¦Á¶µÇ¾î Àå±â°£ ºÐ¼®¹°ÀÇ ¹«°á¼ºÀ» À¯ÁöÇÕ´Ï´Ù. Èֹ߼º ¹ÙÀÌ¿À¸¶Ä¿, ÇÙ»ê, ¹ÙÀÌ·¯½º ÀÔÀÚÀÇ ¾ÈÀüÇÑ ¼öÁý ¹× ¼ö¼ÛÀ» Áö¿øÇϱâ À§ÇØ È­ÇÐÀû ¾ÈÁ¤Á¦ ¹× Ç×±Õ Æ¯¼ºÀ» °¡Áø ÄÚÆÃ Ä«µå°¡ °³¹ßµÇ¾ú½À´Ï´Ù. ÀÌ·¯ÇÑ ¹ßÀüÀ¸·Î DBS Ä«µåÀÇ ºÐ¼® ¹üÀ§°¡ Å©°Ô È®´ëµÇ¾î ±âº»ÀûÀÎ ¹ÙÀÌ¿À¸¶Ä¿ °ËÃâ»Ó¸¸ ¾Æ´Ï¶ó À¯ÀüÀÚ ½ºÅ©¸®´×, ºÐÀÚÁø´Ü, Â÷¼¼´ë ¿°±â¼­¿­ ºÐ¼®(NGS) ¿öÅ©Ç÷ο쿡µµ ÀûÇÕÇÕ´Ï´Ù. ÀÚµ¿ ÆÝĪ ½Ã½ºÅÛ°ú ·Îº¿ »ùÇà Çڵ鷯¸¦ ÅëÇØ ½ÇÇè½Ç¿¡¼­ ¼öÀÛ¾÷À¸·Î ÀÎÇÑ ÆíÂ÷¸¦ ÁÙÀ̰í, ÃßÃâ ±â¼úÀÇ Çâ»óÀ¸·Î ´õ ÀûÀº ¾çÀÇ »ùÇÿ¡¼­ ´õ ³ôÀº ǰÁúÀÇ ºÐ¼®¹°À» ȸ¼öÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ½ÇÇè½ÇÀº ÀÌÁ¦ DBS Ä«µå¿¡¼­ ¾òÀº »ùÇÃÀ» »ç¿ëÇÏ¿© LC-MS/MS, ELISA, PCR, ÀüÀå À¯Àüü ºÐ¼®°ú °°Àº °í°¨µµ ºÐ¼®À» ¼öÇàÇÒ ¼ö ÀÖÀ¸¸ç, QR ÄÚµå ¹× Å¬¶ó¿ìµå ±â¹Ý ½Ã·á ÃßÀûÀ» Æ÷ÇÔÇÑ µðÁöÅÐ ÃßÀû¼º ¼Ö·ç¼Çµµ ÅëÇÕµÇ¾î ½Ã·á °ü¸®¿Í ȯÀÚ µ¥ÀÌÅÍÀÇ ¿¬°á¼ºÀ» °­È­ÇÕ´Ï´Ù. ½Ã·á °ü¸®¿Í ȯÀÚ µ¥ÀÌÅÍÀÇ ¿¬°áÀ» °­È­Çϱâ À§ÇØ ÅëÇյǰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼úÀû ¾÷±×·¹À̵å´Â ÀÓ»ó½ÃÇè, ÀǾàǰ °³¹ß, °øÁß º¸°Ç ÇÁ·Î±×·¥¿¡¼­ DBS Ä«µåÀÇ À¯¿ë¼ºÀ» È®ÀåÇϰí, ÇöÀå Áø´Ü»Ó¸¸ ¾Æ´Ï¶ó Á¤¹Ð °Ë»ç ±â¹Ý ¿ëµµ¿¡¼­µµ °­·ÂÇÑ µµ±¸·Î ÀÚ¸®¸Å±èÇϰí ÀÖ½À´Ï´Ù.

ÀçÅà °Ë»ç¿Í Áý´Ü °ËÁø È®´ë°¡ DBS Ä«µå ¼ö¿ä¸¦ ÃËÁøÇÒ±î¿ä?

¼¼°èÀûÀ¸·Î ¼ÒºñÀÚ ÁÖµµÇü °Ç°­ °ËÁø, ÀçÅà Áø´Ü, ±¹°¡ °ËÁø ÀÌ´Ï¼ÅÆ¼ºê°¡ ºÎ»óÇϸ鼭 °Ç½Ä Ç÷¾× ¹ÝÁ¡ äÃë Ä«µåÀÇ »ç¿ë È®´ë¸¦ À§ÇÑ ºñ¿ÁÇÑ Åä¾çÀÌ Á¶¼ºµÇ°í ÀÖ½À´Ï´Ù. ¿À´Ã³¯ÀÇ ¼ÒºñÀÚµéÀº ÆíÀǼº, ÇÁ¶óÀ̹ö½Ã, µðÁöÅÐ °Ç°­ »ýŰèÀÇ ±Þ¼ÓÇÑ ¼ºÀåÀ¸·Î ÀÎÇØ ÀüÅëÀûÀÎ ÀÓ»ó ȯ°æ ÀÌ¿ÜÀÇ °Ç°­ ¸ð´ÏÅ͸µ¿¡ Àû±ØÀûÀ¸·Î Âü¿©Çϰí ÀÖ½À´Ï´Ù. ÄÝ·¹½ºÅ×·Ñ °Ë»çºÎÅÍ ½Äǰ ¹Î°¨µµ ÆÐ³Î, È£¸£¸ó ¼öÄ¡ Æò°¡¿¡ À̸£±â±îÁö ¸ðµç °ÍÀ» Á¦°øÇÏ´Â ÀçÅà °Ë»ç ¼­ºñ½º¿¡¼­ DBS äÃë ŰƮ´Â Æí¸®ÇÔ°ú ¿ìÆíÀ¸·Î º¸³¾ ¼ö ÀÖ´Â Çü½ÄÀ¸·Î ÀÎÇØ Á¡Á¡ ´õ ¸¹ÀÌ Ã¤Åõǰí ÀÖ½À´Ï´Ù. ±¹°¡ º¸°Ç ±â°ü°ú NGOµµ ´ë±Ô¸ð Àα¸ °Ç°­ Á¶»ç, ½Å»ý¾Æ ¼±º° °Ë»ç ÇÁ·Î±×·¥, ¹é½Å Á¢Á¾ ¹ÝÀÀ ¸ð´ÏÅ͸µ, ¿ªÇÐ °¨½Ã¸¦ À§ÇØ DBS ±â¹Ý ¼öÁý ¹æ¹ýÀ» Ȱ¿ëÇϰí ÀÖÀ¸¸ç, DBS Ä«µå´Â ½Ã°£ÀÌ Áö³ªµµ, ´Ù¾çÇÑ º¸°ü Á¶°Ç¿¡¼­µµ »ùÇÃÀÇ ¹«°á¼ºÀ» À¯ÁöÇÕ´Ï´Ù. ÇÒ ¼ö Àֱ⠶§¹®¿¡ ÀÇ·á ÀÎÇÁ¶ó°¡ Á¦ÇÑÀûÀÎ ³óÃÌ Áö¿ªÀ̳ª ÀÇ·á ¼­ºñ½º°¡ ºÎÁ·ÇÑ Áö¿ª¿¡¼­ »ç¿ëÇϱ⿡ ¸Å¿ì ÀûÇÕÇÕ´Ï´Ù. ¶ÇÇÑ, ÀÓ»ó½ÃÇè ¹× ºÐ»êÇü ¿¬±¸ ¸ðµ¨¿¡¼­ DBS Ä«µå´Â ¿ø°Ý ¼öÁý ¹× Áß¾Ó ÁýÁᫎ ºÐ¼®À» °¡´ÉÇÏ°Ô ÇÔÀ¸·Î½á Âü°¡ÀÚ µî·Ï ¹× ½Ã·á ¹°·ù¸¦ °£¼ÒÈ­ÇÕ´Ï´Ù. ¿ø°Ý ÀÇ·á Ç÷§ÆûÀº ´ç´¢º´, ½ÉÇ÷°ü Áúȯ, HIV µî ¸¸¼ºÁúȯ °ü¸® ÇÁ·Î±×·¥¿¡ DBS ŰƮ¸¦ ÅëÇÕÇÏ¿© Á÷Á¢ ¹æ¹®ÇÏÁö ¾Ê°íµµ Á¤±âÀûÀÎ ¸ð´ÏÅ͸µÀ» ÇÒ ¼ö ÀÖ°Ô ÇØÁÝ´Ï´Ù. µðÁöÅÐ Çコ ÀÎÅÍÆäÀ̽ºÀÇ ¹ßÀü°ú ÇÔ²² ÀÚ°¡ °ü¸® Áø´Ü µµ±¸¿¡ ´ëÇÑ ½Å·Ú°¡ ³ô¾ÆÁü¿¡ µû¶ó ¼±Áø±¹°ú ½ÅÈï±¹ ½ÃÀå ¸ðµÎ¿¡¼­ DBS Ä«µåÀÇ °¡Ä¡ Á¦¾ÈÀ» °­È­ÇÏ¿© Á¢±Ù¼º, È®À强, ȯÀÚ ÁÖµµÇü Áø´ÜÀ» ½ÇÇöÇÏ´Â Áß¿äÇÑ ¼ö´ÜÀ¸·Î ÀÚ¸®¸Å±èÇϰí ÀÖ½À´Ï´Ù.

°Ç½Ä Ç÷¾× ¹ÝÁ¡ äÃë Ä«µå ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ÁÖ¿ä ¿äÀÎÀº?

°Ç½Ä Ç÷¾× ¹ÝÁ¡ äÃë Ä«µå ½ÃÀåÀÇ ¼ºÀåÀº Áø´Ü ¹× ¹ÙÀÌ¿À »ùÇøµÀÇ ¹Ì·¡¸¦ Çü¼ºÇÏ´Â ±â¼úÀû, ÀÓ»óÀû, ÇൿÀû ¿äÀÎÀÇ Á¶ÇÕ¿¡ ÀÇÇØ ÀÌ·ç¾îÁý´Ï´Ù. ƯÈ÷ Äڷγª19 ÆÒµ¥¹ÍÀÇ ±³ÈÆÀº ¿ø°Ý ¹× ºñÁ¢ÃË½Ä Áø´Ü µµ±¸ÀÇ °¡Ä¡¸¦ °­Á¶Çϰí ÀÖ½À´Ï´Ù. ¸¸¼º Áúȯ°ú °¨¿°ÁõÀÇ À¯º´·ü Áõ°¡´Â Á¤±âÀûÀÎ ¸ð´ÏÅ͸µ°ú ½ºÅ©¸®´×À» À§ÇÑ DBS Ä«µåÀÇ ±¤¹üÀ§ÇÑ »ç¿ëÀ» ÃËÁøÇϰí ÀÖÀ¸¸ç, ƯÈ÷ äÇ÷¿¡ ´ëÇÑ Á¢±ÙÀÌ Á¦ÇÑµÈ ÀÚ¿øÀÌ Á¦ÇÑµÈ È¯°æ¿¡¼­ ÀÌ·¯ÇÑ °æÇâÀÌ µÎµå·¯Áý´Ï´Ù. À¯ÀüÇÐÀû °Ë»ç ¹× ºÐÀÚ»ý¹°ÇÐÀû °Ë»çÀÇ È®´ë·Î ÀÎÇØ Ưº°ÇÑ ³ÃÀå ¹× ¿î¼Û ½Ã½ºÅÛ ¾øÀ̵µ ½±°Ô äÃëÇÒ ¼ö ÀÖ°í Àå±â º¸°üÀÌ °¡´ÉÇÑ °íǰÁú »ý¹°ÇÐÀû ½Ã·á¿¡ ´ëÇÑ ¼ö¿äµµ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. °øÁߺ¸°Ç °¨½Ã, ¸ðÀÚº¸°Ç ÇÁ·Î±×·¥ ¹× ±¹°¡ ¹ÙÀÌ¿À¹ðÅ· ÀÌ´Ï¼ÅÆ¼ºê¿¡ ´ëÇÑ Á¤ºÎÀÇ Áö¿øÀº DBS ¼öÁý ½Ã½ºÅÛ¿¡ ´ëÇÑ ÅºÅºÇÑ Á¦µµÀû ¼ö¿ä ±â¹ÝÀ» Çü¼ºÇϰí ÀÖ½À´Ï´Ù. ¼ÒºñÀÚ¿¡°Ô Á÷Á¢ Á¦°øÇÏ´Â °Ç°­ °Ë»ç¿Í °³ÀÎ ¸ÂÃãÇü ÀÇ·áÀÇ ÀαⰡ ³ô¾ÆÁö¸é¼­ ¹Î°£ Áø´Ü ȸ»ç¿Í À£´Ï½º Ç÷§ÆûÀÌ DBS¸¦ µµÀÔÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, DBS Ä«µå´Â ±âÁ¸ äÇ÷¿¡ ºñÇØ äÇ÷, º¸°ü, ¹è¼Û ºñ¿ëÀÌ Àý°¨µÇ±â ¶§¹®¿¡ ÀÓ»ó ¹× ¿¬±¸¿ë ¸ðµÎ¿¡¼­ °æÁ¦ÀûÀ¸·Î ¸Å·ÂÀûÀÏ ¼ö ÀÖ½À´Ï´Ù. ¿©·¯ Áö¿ªÀÇ ±ÔÁ¦ ±â°üÀÌ DBS¸¦ Áø´Ü ¹× ¾à¸®ÇÐ ¿ëµµ¿¡ È¿°úÀûÀÎ °Ëü Æ÷¸ËÀ¸·Î ÀÎÁ¤Çϰí ÀÖ¾î ÇコÄÉ¾î ¿öÅ©Ç÷ο쿡¼­ DBSÀÇ ¿ªÇÒÀ» ´õ¿í Á¤´çÈ­Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀεéÀÌ °áÇյǾî DBS ¼öÁý Ä«µåÀÇ Àü ¼¼°è º¸±ÞÀÌ °¡¼ÓÈ­µÇ°í ÀÖÀ¸¸ç, ºÐ»êÇü ¹× ¿¹¹æÀû ÇコÄɾîÀÇ ¹Ì·¡¿¡ ÇʼöÀûÀÎ µµ±¸·Î ÀÚ¸®¸Å±èÇϰí ÀÖ½À´Ï´Ù.

ºÎ¹®

Ä«µå À¯Çü(Whatman 903 Ä«µå, Ahlstrom 226 Ä«µå, FTA Ä«µå, ±âŸ Ä«µå À¯Çü), ¿ëµµ(½Å»ý¾Æ ½ºÅ©¸®´× ¿ëµµ, °¨¿°Áõ °Ë»ç ¿ëµµ, Ä¡·áÁ¦ ¸ð´ÏÅ͸µ ¿ëµµ, ¹ýÀÇÇÐ ¿ëµµ, CRO/¿¬±¸ ¿ëµµ, ±âŸ ¿ëµµ), ÃÖÁ¾ ¿ëµµ(º´¿ø ¹× Ŭ¸®´Ð ÃÖÁ¾ ¿ëµµ, Áø´Ü¼¾ÅÍ ÃÖÁ¾ ¿ëµµ, ±âŸ ÃÖÁ¾ ¿ëµµ)

Á¶»ç ´ë»ó ±â¾÷ ¿¹

AI ÅëÇÕ

´ç»ç´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AIÅø¿¡ ÀÇÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â LLM³ª ¾÷°è °íÀ¯ SLM¸¦ Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹ü¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ Å¥·¹ÀÌÆ®µÈ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÍ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº °¨¼Ò, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû ¹× °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Dried Blood Spot Collection Cards Market to Reach US$468.1 Million by 2030

The global market for Dried Blood Spot Collection Cards estimated at US$387.6 Million in the year 2024, is expected to reach US$468.1 Million by 2030, growing at a CAGR of 3.2% over the analysis period 2024-2030. Whatman 903 Card, one of the segments analyzed in the report, is expected to record a 4.3% CAGR and reach US$197.1 Million by the end of the analysis period. Growth in the Ahlstrom 226 Card segment is estimated at 2.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$105.6 Million While China is Forecast to Grow at 6.2% CAGR

The Dried Blood Spot Collection Cards market in the U.S. is estimated at US$105.6 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$93.5 Million by the year 2030 trailing a CAGR of 6.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.2% and 2.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.8% CAGR.

Global Dried Blood Spot Collection Cards Market - Key Trends & Drivers Summarized

Is the Rising Focus on Remote Diagnostics and Decentralized Testing Throwing the Spotlight on Dried Blood Spot Collection Cards?

As healthcare systems worldwide pivot toward decentralized diagnostics and remote patient monitoring, dried blood spot (DBS) collection cards are gaining significant prominence as a minimally invasive, cost-effective, and highly portable biosampling method. DBS cards, which involve collecting small volumes of capillary blood on specialized filter paper, are increasingly used for diagnostic testing, disease surveillance, and therapeutic drug monitoring in both clinical and research settings. Their utility is particularly evident in resource-limited environments where traditional phlebotomy infrastructure is lacking or where cold-chain logistics are infeasible. From infectious disease testing (like HIV and hepatitis) to newborn screening, metabolic disorder detection, and pharmacokinetics, DBS cards are becoming an essential tool for accessible and scalable diagnostics. The COVID-19 pandemic further accelerated the demand for remote testing tools, placing renewed emphasis on DBS cards as part of home testing kits and public health surveillance initiatives. Their compatibility with mail-in diagnostics and ease of long-term sample storage without refrigeration make them especially useful for biobanking and longitudinal studies. As personalized medicine and epidemiological monitoring become more widespread, DBS collection cards are proving to be an efficient, patient-friendly method of enabling mass-scale testing with minimal infrastructure. This evolving demand landscape is positioning DBS cards as a core technology in the shift from centralized lab testing to decentralized, patient-centric healthcare models.

How Are Technological Improvements Enhancing the Accuracy and Applications of DBS Collection Cards?

Innovations in sample collection materials, analytical sensitivity, and laboratory processing are driving the evolution of dried blood spot collection cards from simple field tools to precision diagnostic platforms. Modern DBS cards are manufactured using high-grade filter papers with uniform absorption, defined spot boundaries, and chemical stability that preserve analyte integrity over extended periods. Coated cards with chemical stabilizers or antimicrobial properties are being developed to support the safe collection and transport of volatile biomarkers, nucleic acids, or viral particles. These advancements have significantly expanded the analytical range of DBS cards, making them suitable not just for basic biomarker detection but also for genetic screening, molecular diagnostics, and next-generation sequencing (NGS) workflows. Automated punching systems and robotic sample handlers are reducing manual variability in labs, while improved extraction techniques are enabling the recovery of higher-quality analytes from smaller sample volumes. Laboratories can now perform highly sensitive assays-such as LC-MS/MS, ELISA, PCR, and even whole-genome analysis-using samples derived from DBS cards. Digital traceability solutions, including QR codes and cloud-based sample tracking, are also being integrated to enhance sample management and patient-data linkage. These technological upgrades are expanding the utility of DBS cards in clinical trials, drug development, and public health programs, positioning them as powerful tools not only for field diagnostics but also for precision laboratory-based applications.

Is the Expansion of At-Home Testing and Population Screening Boosting Demand for DBS Cards?

The global rise of consumer-directed health testing, at-home diagnostics, and national screening initiatives is creating fertile ground for the expansion of dried blood spot collection card usage. Consumers today are more willing to participate in health monitoring outside traditional clinical settings, driven by convenience, privacy, and the digital health ecosystem’s rapid growth. At-home testing services-offering everything from cholesterol checks to food sensitivity panels and hormone level assessments-are increasingly adopting DBS collection kits for their simplicity and mail-ready format. National health agencies and NGOs are also leveraging DBS-based collection methods in large-scale population health studies, newborn screening programs, vaccination response monitoring, and epidemiological surveillance. The cards’ ability to retain sample integrity over time and under variable storage conditions makes them highly suitable for use in rural or underserved populations where medical infrastructure is limited. Moreover, in clinical trials and decentralized research models, DBS cards are streamlining participant enrollment and sample logistics by allowing remote collection and centralized analysis. Telemedicine platforms are integrating DBS kits into chronic disease management programs for diabetes, cardiovascular conditions, and HIV, enabling regular monitoring without in-person visits. The rising trust in self-administered diagnostic tools, coupled with advancements in digital health interfaces, is reinforcing the value proposition of DBS cards as critical enablers of accessible, scalable, and patient-driven diagnostics in both developed and emerging markets.

What Are the Key Drivers Fueling Growth in the Dried Blood Spot Collection Cards Market?

The growth in the dried blood spot collection cards market is driven by a combination of technological, clinical, and behavioral factors shaping the future of diagnostics and biosampling. A primary growth driver is the widespread push toward decentralizing healthcare services, particularly in light of lessons learned during the COVID-19 pandemic, which highlighted the value of remote, low-contact diagnostic tools. Rising prevalence of chronic and infectious diseases is prompting broader use of DBS cards for regular monitoring and screening, especially in resource-constrained settings where access to phlebotomy is limited. The expansion of genetic and molecular testing is also increasing demand for high-quality biospecimens that can be collected easily and stored long-term without specialized refrigeration or transport systems. Government support for public health surveillance, maternal and child health programs, and national biobanking efforts is creating a robust institutional demand base for DBS collection systems. The growing popularity of direct-to-consumer health testing and personalized medicine is fueling adoption by private diagnostic firms and wellness platforms. Additionally, the reduced cost of collection, storage, and shipment relative to traditional blood draws makes DBS cards economically attractive for both clinical and research applications. Regulatory bodies in multiple regions are increasingly recognizing DBS as a valid specimen format for diagnostic and pharmacological use, further legitimizing its role in healthcare workflows. Together, these factors are accelerating the global adoption of DBS collection cards and establishing them as an essential tool in the future of decentralized and preventive healthcare.

SCOPE OF STUDY:

The report analyzes the Dried Blood Spot Collection Cards market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Card Type (Whatman 903 Card, Ahlstrom 226 Card, FTA Card, Other Card Types); Application (New Born Screening Application, Infectious Diseases Testing Application, Therapeutic Drug Monitoring Application, Forensics Application, CRO / Research Application, Other Applications); End-Use (Hospitals & Clinics End-Use, Diagnostics Centers End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 36 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â